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Abstract 
    This study was carried in the period from December 2002 to February 
2003. A total of 49 blood samples were collected from mycetoma patients in 
Mycetoma Research Center – Soba Civil Hospital and National Health 
laboratory (ESTAC)- Khartoum State. The group surveyed included: 17(34.7%) 
infected untreated or new patients, 32 (65.3%) infected treated patients, and 
normal control group (16 individual). 
The study showed that males were more affected than females and the 
ratio was 4:1. Most of mycetoma patients were in the age group 15 – 25 years 
old. Students (20.4%), jobless (18.4%) and farmers (14.3%) were more 
affected than other occupations. Algazera State had a highest prevalence of 
mycetoma with (34.7%); next state was Khartoum State (16.3%). 
 The duration of the disease varied from 7 month to 30 years and the 
onsets of the disease in most of patients (73.5%) had no known history of 
trauma. Left foot was the major site of infection (34.7%) and most of patients 
(83.7%) had no family history of mycetoma infection. Eumycetoma infection 
had higher prevalence (59.2%) than actinomycetoma infection (38.8%). 
The drug used for treatment in eumycetoma infection was ketoconazole, 
and in actinomycetoma was a combination of Streptomycin, Septrin and folic 
acid.  
Total white blood cells in most of patients (44.9%) were normal count 
between 4050 - 6000cells ⁄µl. and the mean value in untreated patients was 
6081.5cells ⁄µl, while in treated patients it was 6178.3cells ⁄µl and in non- 
infected control it was 570.9 cells/µl. The mean value of CD4 counts in 
untreated patients was 664.7cells ⁄µl, while in treated patients it was 606.8cells 
⁄µl and was 1010 cells ⁄µl in non- infected control. The mean value of CD8 
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counts in untreated patients was 679.7cells ⁄µl, while in treated patients it was 
720.9cells/µl and in non- infected control it was 639cells/µl.  
The mean values of differential counts of white blood cells in non- 
infected control group were 58%neutrophils, 39%lymphocytes, 2% monocytes 
and 1% esinophils. 
 Differential counts of white blood cells, in untreated patients have the 
mean value of neutrophils was 59%, lymphocytes 36%, monocytes 2% and 
esinophils 1%, while in treated patients the mean value of neutrophils was 
55%, lymphocytes 40%, monocytes 3% and esinophils 2%  
CD4 ⁄ CD8 ratio in all patients was 1.1:1. In new and treated patients the 
ratio was 1.2:1 and in non – infected controls it was 1.6:1.   
CD4 count was numerically higher in infected treated patients 
(710cells/µl) than infected untreated patients (664cells/µl). While CD8 count in 
infected treated (719 cells/µl) was numerically lower than in infected untreated 
patients (1378 cells/µl). 
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  ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
 94ﺧﺬت ﻋﻴﻨﺎت دم ﻣﻦ أ . 3002 اﻟﻲ ﻓﺒﺮاﻳﺮ 2002 ﺗﻤﺖ هﺬﻩ اﻟﺪراﺳﻪ ﻓﻲ اﻟﻔﺘﺮة ﻣﺎﺑﻴﻦ دﻳﺴﻤﺒﺮ         
 - اﺳﺘﺎكﻞﺑﺤﺎث اﻟﻤﺎﻳﺴﺘﻮﻣﺎ ﺑﻤﺴﺘﺸﻔﻲ ﺳﻮﺑﺎ اﻟﺠﺎﻣﻌﻲ وﻣﻌﻤأﻤﺎﻳﺴﺘﻮﻣﺎ ﺑﻤﺮآﺰ ﺷﺨﺺ ﻣﺼﺎب ﺑﻤﺮض اﻟ
 %(56 )23، اﻟﻌﻼج ﺑﻌﺪؤا  ﻣﺮﺿﻲ ﺟﺪد ﻟﻢ ﻳﺒﺪ%(43 )71اﺷﺘﻤﻠﺖ ﻋﻴﻨﺔ اﻟﺒﺤﺚ ﻋﻠﻲ .  وﻻﻳﺔ اﻟﺨﺮﻃﻮم
  . ﺷﺨﺺ ﻏﻴﺮ ﻣﺼﺎب61و،  و اﻧﺘﻬﻮا ﻣﻦ اﻟﻌﻼجأﻣﺮﺿﻲ ﻣﺴﺘﻤﺮون 
.  4:1ﻧﺎث هﻲ ﻹﻟﻲ اإﺎث وآﺎﻧﺖ ﻧﺴﺒﺔ اﻟﺬآﻮر ﻧﺑﺔ ﻣﻦ اﻹﺻﺎإآﺜﺮ  أن اﻟﺬآﻮرأ   اﻇﻬﺮت اﻟﺪراﺳﺔ       
وﻏﻴﺮ اﻟﻌﺎﻣﻠﻴﻦ %( 4.02)اﻟﻄﻼب .  ﺳﻨﺔ52 – 51 ﻣﻦ اﻟﻌﻤﺮﻳﺔآﺜﺮ اﻟﻤﺼﺎﺑﻴﻦ ﺑﺎﻟﻤﺎﻳﺴﺘﻮﻣﺎ آﺎﻧﻮا ﻓﻲ اﻟﻔﺌﺔ أ
ﺳﺠﻠﺖ وﻻﻳﺔ اﻟﺠﺰﻳﺮة . ﺧﺮيﺻﺎﺑﺔ ﻣﻦ ﺑﻴﻦ اﻟﻮﻇﺎﺋﻒ اﻷإآﺜﺮ هﻢ اﻷ%( 3.41)واﻟﻤﺰارﻋﻮن %( 4.81)
  %(.3.61)ﺗﻠﺘﻬﺎ وﻻﻳﺔ اﻟﺨﺮﻃﻮم  %( 7.43)اﻋﻠﻲ ﻧﺴﺒﺔ اﻧﺘﺸﺎر ﻟﻠﻤﺎﻳﺴﺘﻮﻣﺎ 
ﻟﻢ ﻳﺼﺎﺑﻮا %( 4.73)أﻏﻠﺐ اﻟﻤﺮﺿﻲ .  ﺳﻨﺔ03 ﺷﻬﻮر و7ﺗﺮاوﺣﺖ ﻓﺘﺮة ﺣﻀﺎﻧﺔ اﻟﻤﺮض ﺑﻴﻦ         
 وأﻏﻠﺐ %(7.43)ﺻﺎﺑﺔ ﺑﺎﻟﻤﺮض  إ اﻟﻘﺪم اﻟﻴﺴﺮي هﻲ اﻟﻤﻜﺎن اﻷآﺜﺮ .ﻟﻤﺮضﺑﺎﺻﺎﺑﺔ دت ﻟﻺأﺑﺠﺮوح 
  . ﻟﻢ ﻳﻜﻦ ﻟﻬﻢ ﺗﺎرﻳﺦ ﻣﺮﺿﻲ ﻓﻲ اﻟﻌﺎﺋﻠﺔ%(  7.38)اﻟﻤﺮﺿﻲ 
ﻣﺎ اﻟﻤﺎﻳﺴﺘﻮﻣﺎ أﻤﺎﻳﺴﺘﻮﻣﺎ اﻟﻨﺎﺗﺠﻪ ﻋﻦ اﻟﻔﻄﺮﻳﺎت هﻮاﻟﻜﻴﺘﻮآﻴﻨﺎزول  ﺻﺎﺑﺔ ﺑﺎﻟﻟﻌﻼج اﻹ اﻟﻤﺴﺘﺨﺪم ﻟﺪواء    ا    
  . ﺳﺘﺮﺑﺘﻮﻣﺎﻳﺴﻴﻦ واﻟﺴﺒﺘﺮﻳﻦ وﺣﻤﺾ اﻟﻔﻮﻟﻴﻚإﻨﺎﺗﺠﻪ ﻋﻦ اﻟﺒﻜﺘﻴﺮﻳﺎ ﻓﻬﻮ ﻣﺮآﺐ ﻣﻦ اﻟ
 ﺧﻠﻴﺔ 0006 – 0504آﺎﻧﺖ ﻃﺒﻴﻌﻴﺔ ﺑﻴﻦ %( 9.44)        آﺮﻳﺎت اﻟﺪم اﻟﺒﻴﻀﺎء ﻋﻨﺪ أﻏﻠﺐ اﻟﻤﺮﺿﻲ 
ﻣﻴﻜﺮوﻟﻴﺘﺮ ﺑﻴﻨﻤﺎ آﺎﻧﺖ ﻓﻲ \ ﺧﻠﻴﺔ1806 .5و ﻏﻴﺮ اﻟﻤﻌﺎﻟﺠﻴﻦ  أ آﺎﻧﺖ اﻟﻘﻴﻤﺔ ﻓﻲ اﻟﻤﺮﺿﻲ اﻟﺠﺪد.ﻟﻴﺘﺮﻣﻴﻜﺮو \
 ﺧﻠﻴﺔ 9.075ﻣﺎ ﻓﻲ اﻻﺷﺨﺎص اﻟﻌﺎدﻳﻴﻦ ﻓﻘﺪ آﺎﻧﺖ أ ﻣﻴﻜﺮوﻟﻴﺘﺮ\ﺧﻠﻴﺔ 3.8716اﻟﻤﺮﺿﻲ اﻟﻤﻌﺎﻟﺠﻴﻦ 
  .ﻣﻴﻜﺮوﻟﻴﺘﺮ\
وﻟﻴﺘﺮ ﺑﻴﻨﻤﺎ آﺎﻧﺖ ﻣﻴﻜﺮ\ﺧﻠﻴﺔ 7.466 ﻓﻲ اﻟﻤﺮﺿﻲ ﻏﻴﺮ اﻟﻤﻌﺎﻟﺠﻴﻦ 4DCﻣﺘﻮﺳﻂ ﻗﻴﻤﻪ  ﻋﺪد ﺧﻼﻳﺎ         
. ﻣﻴﻜﺮوﻟﻴﺘﺮ\ ﺧﻠﻴﺔ0101ﻦ آﺎﻧﺖ ﻴﺷﺨﺎص اﻟﻄﺒﻴﻌﻴﻣﻴﻜﺮوﻟﻴﺘﺮ وﻓﻲ اﻷ\ ﺧﻠﻴﺔ8.606ﻓﻲ اﻟﻤﺮﺿﻲ اﻟﻤﻌﺎﻟﺠﻴﻦ 
ﻣﻴﻜﺮوﻟﻴﺘﺮ ﺑﻴﻨﻤﺎ آﺎﻧﺖ ﻓﻲ \ ﺧﻠﻴﺔ7.976 ﻓﻲ اﻟﻤﺮﺿﻲ ﻏﻴﺮ اﻟﻤﻌﺎﻟﺠﻴﻦ 8DCﻋﺪد ﺧﻼﻳﺎ ﺔ ﻣﺘﻮﺳﻂ ﻗﻴﻤ
  .ﻣﻴﻜﺮوﻟﻴﺘﺮ\ ﺧﻠﻴﺔ936ﺷﺨﺎص اﻟﻄﺒﻴﻌﻴﻦ آﺎﻧﺖ ﻣﻴﻜﺮوﻟﻴﺘﺮ وﻓﻲ اﻷ\ ﺧﻠﻴﺔ9.027اﻟﻤﺮﺿﻲ اﻟﻤﻌﺎﻟﺠﻴﻦ 
 %85: آﺎن ﻣﺘﻮﺳﻂ اﻟﻘﻴﻤﺔ ﻟﻠﻌﺪد اﻟﺘﻔﺮﻳﻘﻲ ﻟﻜﺮﻳﺎت اﻟﺪم اﻟﺒﻴﻀﺎء ﻓﻲ اﻷﺷﺨﺎص اﻟﻄﺒﻴﻌﻴﻦ آﺎﻷﺗﻲ       
أﻣﺎ ﻓﻲ اﻟﻤﺮﺿﻲ ﻏﻴﺮ اﻟﻤﻌﺎﻟﺠﻴﻦ .  اﻳﺰﻳﻨﻮﻓﻴﻞ%1 وﺣﻴﺪات ﺧﻠﻴﺔ و %2 ﺧﻼﻳﺎ ﻟﻴﻤﻔﻴﺔ ،%93ﻧﻴﺘﺮوﻓﻴﻞ، 
 v
 
اﻳﺰﻳﻨﻮﻓﻴﻞ، ﺑﻴﻨﻤﺎ آﺎﻧﺖ ﻓﻲ  %1 وﺣﻴﺪات ﺧﻠﻴﺔ و %2 ﺧﻼﻳﺎ ﻟﻴﻤﻔﻴﺔ ،%63  ﻧﻴﺘﺮوﻓﻴﻞ، %95: ﻓﻜﺎﻧﺖ
  . اﻳﺰﻳﻨﻮﻓﻴﻞ%2 وﺣﻴﺪات ﺧﻠﻴﺔ و %3 ﺧﻼﻳﺎ ﻟﻴﻤﻔﻴﺔ ،%04  ﻧﻴﺘﺮوﻓﻴﻞ، %55:اﻟﻤﺮﺿﻲ اﻟﻤﻌﺎﻟﺠﻴﻦ 
ﻓﻲ اﻟﻤﺮﺿﻲ ﻏﻴﺮ اﻟﻤﻌﺎﻟﺠﻴﻦ واﻟﻤﻌﺎﻟﺠﻴﻦ آﺎﻧﺖ . 1:1.1ﻓﻲ آﻞ اﻟﻤﺮﺿﻲ 8DC⁄4DC ﻧﺴﺒﺔ   
  .1:6.1ﻦ ﻓﻜﺎﻧﺖ ﻴﺷﺨﺎص اﻟﻄﺒﻴﻌﻴ أﻣﺎ ﻓﻲ اﻷ1:2.1
ﻋﻦ ﻏﻴﺮ ( ﻣﻴﻜﺮوﻟﻴﺘﺮ\ ﺧﻠﻴﺔ017) ﻟﻤﺮﺿﻲ اﻟﻤﻌﺎﻟﺠﻴﻦ ﻋﺪدﻳﺎ أﻋﻠﻲ ﻓﻲ ا4DCآﺎﻧﺖ ﺧﻼﻳﺎ   
 917) ﻋﺪدﻳﺎ أﻗﻞ ﻓﻲ اﻟﻤﺮﺿﻲ اﻟﻤﻌﺎﻟﺠﻴﻦ  8DC، ﺑﻴﻨﻤﺎ آﺎﻧﺖ ﺧﻼﻳﺎ (ﻣﻴﻜﺮوﻟﻴﺘﺮ\ ﺧﻠﻴﺔ466)اﻟﻤﻌﺎﻟﺠﻴﻦ 
  . (ﻣﻴﻜﺮوﻟﻴﺘﺮ\ ﺧﻠﻴﺔ8731)ﻋﻦ ﻏﻴﺮ اﻟﻤﻌﺎﻟﺠﻴﻦ ( ﻣﻴﻜﺮوﻟﻴﺘﺮ\ﺧﻠﻴﺔ
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Introduction 
Mycetoma is a major health problem in tropical and subtropical 
areas. Although Sudan seems to be the mycetoma home land, the disease 
is badly neglected in this country. For various understandable reasons its   
true prevalence in the Sudan remains unknown. Based on the records of 
the Ministry of Health – Sudan, 1729 hospital attendances for mycetoma 
were reported in the years 1951 – 1952(Lynch, 1964). In 1956, 1231 
cases of mycetoma were reported as having been admitted to hospitals or 
were seen at out patients departments over a period of 30 month (Abbott, 
1956). Lynch (1964) conservatively estimated the incidence of mycetoma 
as 300 – 400 cases per annum. Mograby (1967) on reviewing Wad 
Madani Civil Hospital records reported 817 mycetoma patients in the 
years 1955 to 1964. Mahgoub (1989) from the Mycetoma Clinic at 
Khartoum North and records of the Ministry of Health reported an 
incidence of 365 new cases per year 1971 – 1975.  
Economically, and because of the commonest site for mycetoma is 
the foot, this may affect the performance of the patient and this will   
decrease the income and so the economics of the country. 
This study try to express  epidemiology and prevalence of disease 
in different states of the Sudan and  to provide an idea about the effect of 
mycetoma infection on the immune system mainly on CD4 and CD8 T 
lymphocyte counts and the correlation of the count with treatment. 
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Objectives 
This study attempt to : 
1-  To study the epidemiology and prevalence of mycetoma infection 
in Sudan. 
2- To determine counts of CD4, CD8 T- lymphocytes and TWBCs in 
mycetoma patients.  
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Chapter One 
 Literature Review 
1.1 Mycetoma: 
    Mycetoma is a chronic subcutaneous infection caused by 
actinomycetes or fungi. This infection results in a granulomatous 
inflammatory response in the deep dermis and subcutaneous tissue, which 
can extend to the underlying bone. Mycetoma is characterized by the 
formation of grains containing aggregates of the causative organisms that 
may be discharged onto the skin surface through multiple sinuses. This 
disease was described first in the mid 1800s and initially named Madura 
foot, after the region of Madura in India where it first was identified. 
Both actinomycetoma and eumycetoma prevail in Sudan.    
1.1.1The etiology of mycetoma: 
    Mycetoma can be caused by true fungi (eumycetoma) or aerobic 
actinomycetes which are higher filamentous bacteria. Eumycetoma can 
be caused by various fungi which produce grains of different sizes, colors 
and consistency depending on the causative agent .The more common 
ones that cause big black and hard grain approximately 1mm diameter 
eumycetoma include, Maduerlla mycetomatis, Maduerlla grisea, 
Leptosphria senegaliensis, Pyrenochaeta romeroi, Philolphore jenselmi , 
Curvularia lunata. Other eumycetoma produce big white grains like: 
Peterilidium boydii, Aspergillus nidulans. Some produce hard brown 
grains like Neotestudina rosatii. Rarely, A. flavus can cause eumycetoma 
and a case of a green grain eumycetoma due to A. flavus has been 
reported by Mahgoub in 1973. 
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    Actinomycetes include: Streptomyces somaliensis (small, hard, dirty 
yellow grains), Actinomadura madurae (big, soft, white grains), 
A.pelletieri (tiny, hard, red grains), Nocardia species which include 
N.brasiliensis, N.asteriods and N.otitidiscavarium which previously 
known as N.caviae (small, beige-yellow or orange grains). 
1.1.2 Pathology: 
 Mycetoma is a chronic granulomatous subcutaneous infection 
caused by actinomycetoma or by true fungi i.e. eumycetoma. It is 
characterized by the formation of aggregates of the organism in form of 
grains in the tissues which are visible to the naked eye. The grains vary in 
colour, size and consistency depending on the mycetoma causative agent. 
These features are helpful in making a tentative diagnosis of the causative 
organism (Gonzalez-Ochoa, 1975). A definitive identification of the 
agent is established by the histological examination of the grains, by 
culture and ⁄ or by serological techniques (Frey et al., 1981, Gumaa and 
Mahgoub, 1975, Gumaa and Mahgoub, 1973; Taha, 1983). 
1.1.2.1 Bone change in mycetoma: 
 Bones frequently involved in advanced mycetoma of the host 
tissue. Occasionally primary bone mycetoma with the absence of soft 
tissue involoment is seen. Madurella mycetomatis produces lytic lesions 
which are large in size, few in number and have well defined margins 
(Fahal and Hassan, 1992). Actinomycetoma destroys bone and also 
evokes new bone formation. The cavities produced are usually smaller in 
size, numerous and have no definite margins (Fahal and Hassan, 1992). 
 
5 
 
1.1.2.2 Secondary bacterial infection: 
   In Sudan, most of the patients with mycetoma, especially those 
with eumycetoma, are susceptible to secondary bacterial infection in their 
lesions (Abdallah et al.,1998). These results contradict the previous 
impression that the sinuses’ discharge is usually sterile due to antibiotics 
produced by the fungi (Fahal and Al Hassan, 1992). Upon testing the M. 
mycetomatis strains for antibiotic production, no such inhibitory 
compounds to which standard clinically relevant bacterial species were 
susceptible were detected. S. aureus appeared to be the most-common 
pathogen in this type of infection.   
  A high prevalence of secondary bacterial infection has been found 
in lesions of patients suffering from various types of mycetoma. SBI 
appears to be a serious problem in mycetoma. It may cause pain and 
increased disability. Moreover, some superinfected patients develop 
concomitant bacteremia or septicemia which incidentally results in death 
(Magana, 1984).   
1.1.2.3 Mycetoma sites: 
Mycetoma in general involves those parts of the body that come in 
contact with soil during standing, sitting or laying down. The commonest 
site for mycetoma is the foot which accounts for 70% of cases, most of 
the lesions are seen on the dorsal aspect of the forefoot and for un 
explainable reasons the left foot is more affected (Mahgoub and Murray, 
1973; Magana, 1984; Abbott, 1965; Fahal et al., 1992). The hand is the 
next commonest site which occurs in 12% of cases (Murray, 1960; 
Mahgoub, 1985; Tight and Bartlell, 1981). In endemic areas other parts of 
body may be involved but less frequently, the knee, arm, leg, head and 
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neck, thigh and the perineum are affected in that order (Soretain and 
Mariat, 1984; Amin and ElGaali, 1986; El Bashir et al., 1987;  Brijesh et 
al., 1984). Rare sites such as the chest, abdominal wall, fascial bones, 
mandibles, testes, para nasal sinuses, eye lid and surgical incision sites 
may be affected (Aldrige and Kirk, 1940; Gumaa et al., 1975; Crockett, 
1968; Fahal et al., 1994). Visceral Mycetoma had not been reported yet.  
The  foot was the most common mycetoma  site  in in-patient in Wad 
Madni and Khartoum Hospitals and was estimated  to be 78% (Abbott, 
1954), 76.3% (Murray, 1960) and 70-80% (Mogharaby, 1967). The 
second site is the leg 10% (Abbott, 1954), 5.3% (Murray, 1960) and 4% 
(Mogharaby, 1967). The third site is the hand 6% (Abbott, 1954), 13% 
(Murray, 1954) and 10% (Mogharaby, 1967). Other sites e.g. thigh and 
knee 6% (Mogharaby, 1967).  
1.1.2.4 Multiple lesions: 
 Fahal (1995) reported that 4.4% of patients had more than one 
lesion at different site, 11% were male and 8.3% were female, whereas 
Mubarak (1991) reported that 8(2.4%) patients out of 334 patients had 
double lesion. 
1.1.2.5 Clinical presentation of mycetoma: 
The clinical presentation is almost identical irrespective of the causal 
organism. However, the rate of progress is more rapid with 
actinomycetoma than with eumycetoma. In eumycetoma, the lesion 
grows slowly with clearly defined margins and remains encapsulated for 
a long period whereas in actinomycetoma the lesion is more 
inflammatory, more destructive and invades the bone at an earlier period ( 
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Mahgoub and Murray, 1973; Chadfield, 1964; Hay and Mackenzie, 1983; 
Oyston, 1961;   Manson, 1987).  
The clinical picture of mycetoma may be influenced by one or a 
combination of the following factors: the duration of the disease, the 
causative organism, the site of the infection and the immune response of 
the host. 
1.1.2.7 Pain: 
Mycetoma is usually painless in nature because it is assumed that, 
the organism produces substances which have an anesthetic action 
(Gumaa, 1983). In about 18% of cases, patients may seek medical advice 
for the pain; it may be produced by the expansion of the bone with the 
mycetoma or due to secondary bacteria infection (Fahal, et al., 1992). At 
a late stage of the disease the pain may become negligent due to nerve 
damage by the tense fibrous tissue reaction, dendritis or poor 
vascularization of the nerve (Mahgoub and Murray, 1973). 
1.1.3 Epidemiology:  
 The incidence and a etiological agents of mycetoma whether fungi 
or actinomycetoma show distinct geographical differerances. The disease 
occurs in many parts of the world but more commonly in tropical and 
subtropical countries of Africa, the Middle East and other parts of Asia 
and South America (Mariot et al., 1977). There is a mycetoma belt which 
lies between latitudes 15º S and 30º N of equator where there is a higher 
incidence in savannah region than in desert or tropical forests. In this 
region most of the rainfalls are during a season lasting 3-4 months. The 
remaining 8-9 months are hot and dry which favour the growth of Acacia 
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trees which have big thorns that may play a role in introducing the 
organism from the soil into the body.  
 The prevalence of one type of organisms or another at certain area 
depends on several topographical factors such as temperature, rainfall 
(Mariot, 1963), type of soil, prevalent vegetation and demographic 
features of the susceptible population. 
  In Africa, most mycetoma cases are eumycetoma caused mainly by 
Madurella mycetomatis. This is the commonest agent of Mycetoma in 
Sudan, India and other tropical areas of Africa, but less so in Somalia, 
Yemen and Saudi Arabia. In Somalia, actinomycetoma is more common 
than eumycetoma with S.somaliensis as predominant. Actinomycete 
followed by A.madurae  (Panhajalakshmi and Taralakshmi, 1984)  and 
then M.mycetomatis as the commonest agent of eumycetoma. In Saudi 
Arabia, the incidence is the same but infection with N.asteriods also 
occurs (Bendle, et al., 1987). Few cases have been reported by AL-Mofti 
et al. (1965) in Upper Egypt and were all caused by M. mycetomatis. In 
central Europe, the disease is rare but cases have been reported by Mariot 
(1963) in Romania and Italy. 
 In temperate regions, Petrielliedium boydii is the commonest cause 
of eumycetoma. In fact, it is the commonest cause of eumycetoma in the 
United States and has been isolated from soil in United States and 
Canada. In a comprehensive study carried out by Mariot in 1963, 
N.brasiliensis was found to be the commonest agent of actinomycetoma 
in central and South America and in recent study, it was found to account 
for 85.6% of actinomycetoma cases in Mexico. This is followed 
A.madurae, S.somaliensis and A.pelletieri (Buot et al., 1987). 
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 Nocardia are usually the causative organisms of mycetoma in 
temperate region (Mahgoub and Murray, 1973; Mariate, 1963). 
1.1.3.1 Route of entry: 
 The organism is usually presents in the soil in the form of grains. 
After they are moisturized by rain, they form conidia or other forms able 
to infect the host. This infectious agent is then implanted into the host 
tissue through a breach in the skin produced by trauma caused by sharp 
objects such as thorn pricks, stone or splinters. However in many patients 
there is no history of trauma at the site of infection. In areas where 
mycetoma is frequent, the habit of going barefooted is common and 
thorns are plentiful. As a result, natural infection expected to be more 
frequent than it actually is, if this theory of route of infection is true. The 
disease is not contagious from person to other or from animal to human     
(Mahgoub and Murry, 1973; Abbott, 1965; Lynch, 1964). 
 Out of 792 patients of mycetoma, 159 patients (21%) showed local 
trauma in the site of infection, while 101 (13.5%) gave no history of 
trauma, whereas majority of patients (65.2%) were not sure of such 
history. The highest incidence of trauma (70%) was seen in patients in 
group 30-40 years (Fahal, 1995). 
1.1.3.2 Incubation periods: 
  The incubation period in mycetoma is unknown due to the 
difficulty in establishing the time of initial infection. However in 
experimental animals the formation of the granuloma was noted after a 
period of 3 weeks from inoculation of organism (Mahgoub and Murry, 
1973; Abbott, 1965; Lynch, 1964; Magana, 1984). 
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1.1.3.3 Duration: 
The duration of the disease varies between the three months to 30 
years. Patients tend to present late with advanced disease. This may be 
due to the nature of the disease which is painless and slowly spreading. 
Further lack of health education, shyness if the lesion is in the perineum 
or the inguinal region or the fear of many patients from the available 
therapeutic modalities may be responsible to the delay (Mahgoub and 
Murray, 1973; Bocarro, 1909; Singh, 1978). Fahal (1995) reported that 
the duration varied from 3 month to 50 years and most patients with 
eumycetoma infection (34%) had disease for 1-5 years, whereas (18.8%) 
of actinomycetoma patient had it for the same duration. 
1.1.3.1 Age: 
No age is exempted but, it commonly affects adults between 20-40 
years old of age, the earning members of the society, however, in 
endemic regions children and elderly people may also be affected 
(Develoux et al., 1988; Agarwal et al., 1985; Basset et al., 1965). In fact 
cases have been seen in children 4-5 years old and in elderly above 70 
years old (Gumaa, 1994). Fahal in 1995 reported that, from 552 
eumycetoma patient majority of them (76.4%) were in the age group 11-
30 years, while in 220 actinomycetoma patients, most of them (53.2%) 
were in the same age group.  
1.1.3.2 Sex: 
 In Sudan, males are affected more than females in the ratio of 5:1 
(Abbott, 1956). This is genuine sex difference and is not related to the 
greater outdoor activities of males because in certain areas in Sudan, 
males and females go out to work in the fields side by side. Fahal in 1995 
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reported that from 552 eumycetoma patients 80% were male and 20% 
were female with male to female ratio 4:1, while in 220 actinomycetoma 
patients 73.2% were male and 26.3% were female with male to female 
ratio 2.7:1. 
1.1.3.3 Occupations:  
 Since mycetoma agents have been isolated from soil and vegetation 
in endemic areas, naturally the disease prevails in those people who come 
in direct contact with the soil like farmers, cultivators, wood cutters and 
herdsmen, but no occupation is exempted. Mycetoma has been seen in 
several people with different occupations like doctors, teachers, nurses, 
drivers and students (Gumaa, 1994). In study of 792 mycetoma patients 
30.2% were student and 14.8% were farmers (Fahal, 1995). Mubarak in 
1991 reported that 44.2% had outdoor occupations i.e. farmers, manual 
workers, drivers, etc… 
1.1.3.4 Mortality/Morbidity:   
The disease causes disfigurement but rarely is fatal; however, when 
the skull is involved, a risk to life exists. The lesions are painless and 
slowly progressive; but, pain may occur when secondary bacterial 
infection or bone expansion occurs. In advanced cases, deformities or 
ankylosis and their corresponding disabilities can appear. Patients who 
are immunocompromised or who have undergone transplantation can 
develop invasive infection (Basilio et al., 2007). 
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1.1.4 Immunology: 
1.2.1.1 Innate immunity: 
  Innate immune defenses are non-specific, meaning these systems 
recognize and respond to pathogens in a generic way (Alberts et al., 
2002). This system does not confer long-lasting immunity against a 
pathogen. The innate immune system is the dominant system of host 
defense in most organisms (Beck et al.,   1996).   
 The accumulation of leucocytes at the sites of inflammation is a 
primary mechanism by which the immune system localizes and destroys 
antigenic materials. Under normal circumstances the inflammatory 
process is the mechanism of innate immunity. While the inflammatory 
response is abnormal in case of immunodeficiency infectious disease can 
ensue. As it was documented that mycetoma, have deficiency in cell 
mediated immune response (Mahgoub et al., 1977) and the 
immunoglobulins detected in mycetoma are not protective against the 
disease agents but serve as diagnostic in precipitin and counter current 
immunoelectrophoresis (CIE). Polymorphonuclear leukocyte are effecters 
of acute inflammation; in addition to their phagocytic potential, they 
contain potent digestive enzymes and lysosmal granules and are able to 
secrete toxic O2 radicals for the destruction of foreign materials. Such 
toxic materials are released extracellularly and in case of mycetomas they 
destroy skin, subcutaneous, cutaneous, superficial and deep fascia and 
bones. 
1.2.1.3 Humoral immunity: 
 The humoral immune response (HIR) is the aspect of immunity that is 
mediated by secreted antibodies, produced in the cells of the B 
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lymphocyte lineage (B cell). Secreted antibodies bind to antigens on the 
surfaces of invading microbes (such as mycetoma), which flags them for 
destruction (Pier et al., 2004). Humoral immunity is called as such, 
because it involves substances found in the humours, or body fluids. 
 Both precipitation and complement fixing antibodies form in 
mycetoma infection. They are increased with activity and fall with 
recovery disappearing with cure. Precipitation antibodies are used in the 
diagnosis and monitoring treatment. They are measured by 
immunodifiusion test (ID), counter current immunoelectrophoresis, both 
of which are sensitive and specific. Complement fixing antibodies are 
less specific (Manson, 1987). 
   Mycetoma patients seems to be deficient in their cell mediated 
immunity as measured by tuberculin test, dinitro-chlorobenzene reaction 
and lymphocyte transformation test, but type four skin reactions are 
produced to purified protein antigens in actinomycetoma and some cases 
of eumycetoma with madurella antigens (Mahgoub, 1968). 
1.2.1.4 Cell Mediated immunity: 
  Cell-mediated immunity, also known as delayed-type 
hypersensitivity (DTH), is an immune response that does not involve 
antibodies but rather involves the activation of macrophages, natural 
killer cells (NK), antigen-specific cytotoxic T-lymphocytes, and the 
release of various cytokines in response to an antigen. 
Cell-mediated immunity is directed primarily at microbes that survive in 
phagocytes and microbes that infect non-phagocytic cells. It is most 
effective in removing virus-infected cells, but also participates in 
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defending against fungi, protozoans, cancers, and intracellular bacteria. It 
also plays a major role in transplant rejection (Houghton, 2000, 2004) 
 Mahgoub et al. (1977) studied the cell mediated immunity of a 
group of mycetoma patients by means of tuberculin testing, sensitization 
with dinitrochlorobenzine (DNCB) and lymphocyte transformation, they 
found defective T cell mediated responses especially in those patients that 
were not responding well to treatment. The finding was supported by the 
fact that eumycetoma could be induced in naturally athymic mice but not 
in normal mice   (Mahgoub, 1981).  
1.1.5 Diagnosis: 
1.1.5.1 Microscopy appearance and Culture: 
1.1.5.1.1 Madurella mycetomatis: 
 In clinical material, the grains in the tissue are black and numerous. 
In stained sections the grain is rounded, oval or trilobed. It has a more 
compact cortex which is dark brown in colour due to pigment produced 
by the organism and has a lighter medulla. In some grains the division 
into cortex and medulla is not evident. The grain filaments are usually 
embedded in a hard brown cement matrix (Fery et al., 1981). 
 Two main morphological types of grains are identified. The 
filamentous, which is the commonest type consist of brown septate and 
branched hyphae that may be slightly more towards the periphery. In the 
cortex, the filaments are arranged radially while in the medulla they tend 
to run multi-directionally. Rounded and oval cells, 7-15µm in diameter 
are seen particularly in the periphery   (Fery et al., 1981). 
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 The second type of grain is the vesicular one. It is less common 
than the filamentous and is composed of unusually large cells which look 
like vesicles. Both types can be found in the same lesion. Grains that are 
partially vesicular and partially filamentous are not commonly seen. 
 Ultrastructural studies of the host reaction show neutrophils 
adherent to the grain. The cytoplasm of the neutrophil is stretched over 
the grain and the neutrophils granules are concentrated in the part of the 
cytoplasm adjacent to the grain. This is an immuno adherence which is 
mediated by immunoglobulins and it is an example of antibody dependent 
cell mediated immunity (Fery et al., 1981).   
1.1.5.1.2 Streptomyces somaliensis:   
 The grains are yellow and hard. In sections they appear rounded to 
oval, dense and homogenous (Fery et al., 1981). Characteristically, marks 
of the microtome knife are seen in the grain in the form of parallel cracks. 
The grain stains a light purple or pink colour in haematoxylin and eosin 
stained sections. The grain varies in size from 30 to 200 µm. Hyphae 
elements embedded in cement can be visualized by Gram stain (Fery et 
al., 1981).  It is surrounded by an intense neutrophil polymorphonuclear 
leucocyte. Outside this zone, there is a vascular layer containing 
macrophgage, lymphocyte, plasma cells and giant cells. The giant cells 
usually contain fragments of the grain. Some macrophages have foamy 
cytoplasm which looks as though the fragmentation of the grain induced 
by neutrophils is less severe than in Madurella mycetomatis. This  may be 
due to the more compact and hard grains of Streptomyces somaliensis. 
Small grains surrounded by macrophages and giant cells are occasionally 
seen but pure epitheloid granulomas apparently does not occur. Giant 
cells containing viable actinomycetes are believed to aid the spread of the 
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organism in the tissue (Lynch, 1964) and to the regional lymph nodes. 
Despite the invasive nature of Streptomyces somaliensis and other 
actinomycetes, tendons and nerves are resistant to invasion. 
 Ultrastrucurally the grain consists of heterogenous and amorphous 
matrix arranged in an irregular and reticulated structure surrounding 
electron lucent areas measuring between 1 and 5µm   (Nasher et al., 
1987). In some of these spaces bacterial filament are found. The 
organisms are usually unicellular and coccoid and the cell wall is electron 
dense. 
1.1.5.1.3 Actinomadura pelletieri:    
  The grains in clinical material are tiny and red in colour (Fery et 
al., 1981). In section the grain is rounded, oval or semi lunar. It stains a 
purple and compact hyphae give it the appearance of "iron filings". The 
periphery has a narrow deeply esinophilic band. The grain is usually 
surrounded by a zone of neutrophils which causes fragmentation of the 
grain. The other layers are similar to those seen in Streptomyces 
somaliensis. However, the giant cells are less conspicuous. 
 The ultra structure of the grain is quite distinctive. The hyphae are 
septate, compact without cement substance and under low magnification 
the hyphae have a starry sky appearance because of the vacuoles. 
Neutrophils usually adhere to the grain and degranulate. 
1.1.5.1.4 Actinomadura madurae: 
 Macroscopically the grains are yellow or white (Fery et al., 1981). 
They are difficult to distinguish from the surrounding fat. The periphery 
is dense, large and homogenous and deep purple which is not seen in 
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Actinomadura pelletieri while the centre is less dense or even appears 
hollow.  
1.1.5.2 Serology: 
 Serological tests are useful in the diagnosis, and in a follow up of 
patient on treatment. The time honored tests in this area are 
immunodiffusion (ID) and counter-current-immunoelectrophoresis (CIE). 
These tests have been used extensively in diagnosis, and in follow-up of 
patients. Both tests are sensitive and specific, except for some cross-
reactivity among the actinomycetes. Both tests were found less sensitive 
in case of eumycetoma especially with Madurella mycetomatis. This 
could be explained by strain variations. Use of pooled antigens from 
different strains may improve sensitivity in these cases (Mahgoub and 
Murray,   1966, 1973).   
1.1.5.3 Mycetoma radiology: 
 A series of radiological changes are seen in mycetoma. These are 
due to the fact that all mycetoma agents are osteophilic and due to the 
effect of granuloma on both the affected bones and its blood supply. 
These changes are clearly demonstrated with N.brsiliensis and with 
A.pelletieri infection, which are the most destructive and osteolytic 
mycetoma agent. 
 The changes are average with S.somaliensis and A.madurae, are 
minimal and late with M.mycetomatis (Davies, 1985; Cockshott, 1968; 
Lewall et al., 1985; Bendle et al., 1987;  Kamalam, 1975).  
 Radiology, as a mean of diagnosis of mycetoma, is not 
advantageous in the early stage of the disease but, in late it demonstrates 
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the presence and extents of the soft tissue mass and bone involvement. It 
may be of a prognostic value and may be useful for follow up of patients 
during medical treatment (Fahal et al., 1992). 
1.1.6 Treatment: 
Combating Mycetoma requires both surgery and drug therapy. Surgery 
usually consists of removing the tumor and a portion of the surrounding 
tissue. If the infection is extensive, amputation is sometimes necessary. 
Drug therapy is recommended in conjunction with surgery. The specific 
prescription depends on the type of bacteria or fungi causing the disease. 
Common medicines include antifungal drugs, such as ketoconazole and 
antibacterial (streptomycin sulfate, amikacin, sulfamethoxazole, 
penicillin, and rifampin) (McGinnis and Michael, 1996) 
1.1.6.1 Actinomycetoma:  
Standard treatment is a combination of streptomycin and cortrimoxazole, 
but if there is no response, a combination of streptomycin with one of the 
following drugs is given: Dapsone, sulphadoxine-pyrimethamine, 
fansidar and rifampicin (Mahgoub, 1994).  
1.1.6.2 Eumycetoma:  
         In cases of eumycetoma due to M.mycetomatis which constitutes the 
major causative agent in tropical and subtropical Africa and Asia, the 
drug of choice is ketoconazole (Mahgoub and Gumaa, 1984), however it 
is not effective in mycetoma caused by P.boydii or Acrremonium species 
(Hay et al., 1992).Other regime include, procaine penicillin. 
Mahgoub (1976) published methods for in vitro testing of 
mycetoma organisms and reported on the medical management of 144 
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patients with actinomycetoma caused by Streptomyces somaliensis, 
Actinomadura madurae and A. pelletieri out of these patients, 63% were 
cured by one or other combination of antibiotic or chemotherapeutic 
agents namely streptomycin, together with dapsone, or with co-
trimoxazole, or with Sulphadoxin pyrimamine or wih rifampicin. This 
publication found a wide circulation to the extent that it is now globally 
accepted as treatment of actinomycetoma. In an updated review of 
treatment of actinomycetoma a new antibiotic has been added, 
i.e.amikacin sulfate. It can be used alone or in a combination with 
cortrimoxazole (Hay et al., 1992; Welsh et al., 1987). 
          The problem of treating mycetoma due to M. mycetomatis 
remained unsolved for quite a time, and once more success of treatment 
with Ketoconazole was reported from Sudan by Mahgoub and Gumaa 
(1984). In a series of 13 patients five were cured and four greatly 
improved by daily intake of Ketoconazole. 
1.1.7 Surgical care: 
Basilio et al. (2007) said that surgery is recommended for localized 
lesions that can be excised completely without residual disability. 
Surgical reduction of large lesions can improve the patient's response to 
medical treatment; however, partial surgical resection without subsequent 
use of appropriate antimicrobial or antifungal agents is prone to failure. 
1.2.1.5 Lymphocytes: 
The cells of the adaptive immune system are a type of leukocyte, 
called a lymphocyte. B cells and T cells are the major types of 
lymphocytes. The human body has about 2 trillion lymphocytes, 
constituting 20–40% of the body’s white blood cells; their total mass is 
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about the same as the brain or liver (Alberts et al., 2002).  The peripheral 
blood contains 20–50% of circulating lymphocytes; the rest move within 
the lymphatic system (Alberts et al., 2002).  
B cells and T cells are derived from the same pluripotential 
hemopoietic stem cells, and are indistinguishable from one another until 
after they are activated (Janeway  et al., 2005).  B cells play a large role in 
the humoral immune response, whereas T-cells are intimately involved in 
cell-mediated immune responses. B-cells may be named for the bursa of 
Fabricius, an organ unique to birds, where the cells were first found to 
develop. However, in nearly all other vertebrates, B cells and T-cells are 
produced by stem cells in the bone marrow (Janeway  et al., 2005).  T-
cells travel to and develop in the thymus, from which they derive their 
name. In humans, approximately 1-2% of the lymphocyte pool 
recirculates each hour to optimize the opportunities for antigen-specific 
lymphocytes to find their specific antigen within the secondary lymphoid 
tissues. 
1.2.1.5.2 Helper T cells: 
Helper T cells regulate both the innate and adaptive immune 
responses and help to determine which types of immune responses the 
body will make to a particular pathogen (Harty and Tvinnereim, 2000; 
Radoja et al., 2006).  These cells have no cytotoxic activity and do not 
kill infected cells or clear pathogens directly. They instead control the 
immune response by directing other cells to perform these tasks. 
1.2.1.5.1 Cytotoxic T- Lymphocytes: 
  Are a sub-group of  T cells that kill cells infected with viruses and 
other pathogens, or are otherwise damaged or dysfunctional (Pancer and 
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Cooper, 2006).  As with B cells, each type of T cell recognizes a different 
antigen.  
1.2.1.5.3Natural-killer-cell:      
Natural killer (NK)   cells are part of a group known as the "large 
granular lymphocytes". These cells are generally non-specific, MHC-
unrestricted cells involved primarily in the elimination of neoplastic or 
tumor cells. 
1.2.1.5.4Killer-cell:   
Killer-cells (K- cells) are probably not a separate cell type but rather a 
separate function of the NK group. K-cells contain immunoglobulin Fc 
receptors on their surface and are involved in a process known as 
antibody-dependent cell-mediated cytotoxicity (ADCC).   
1.2.2 Cluster of differentiation (CD): 
The cluster of differentiation (CD) is a protocol used for the 
identification and investigation of cell surface molecules present on 
leukocytes. CD molecules can act in numerous ways, often acting as 
receptors or ligands (the molecule that activates a receptor) important to 
the cell. A signal cascade is usually initiated, altering the behavior of the 
cell. Some CD proteins do not play a role in cell signalling, but have 
other numerous functions, such as cell adhesion (Schlossman et al., 
1994). 
1.2.2.1 Nomenclature: 
The CD nomenclature was proposed and established in the 1st 
International Workshop and Conference on Human Leukocyte 
Differentiation Antigens (HLDA), which was held in Paris in 1982. This 
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system was intended for the classification of the many monoclonal 
antibodies (mAbs) generated by different laboratories around the world 
against epitopes on the surface molecules of leukocytes. Since then, its 
use has expanded to many other cell types, and more than 320 CD unique 
clusters and subclusters have been identified. The proposed surface 
molecule is assigned a CD number once two specific monoclonal 
antibodies (mAb) are shown to bind to the molecule. If the molecule has 
not been well characterized, or has only one mAb, it is usually given the 
provisional indicator "w" as in "CDw186"(WHO, 1997). 
1.2.2.2 Uses: 
The CD system is commonly used as cell markers; this allows cells 
to be defined as based on what molecules are present on their surface. 
These markers are often used to associate cells with certain immune 
functions or properties. While using one CD molecule to define 
populations is not uncommon (a few examples include such as the CD3 
molecule with T lymphocytes, CD20 with B lymphocytes, or CD45 with 
all leukocyte groups), combining markers has allowed for cell types with 
very specific definitions within the immune system.  
CD molecules are utilized in cell sorting using various methods 
including flow cytometry. Cell populations are usually defined using a '+' 
or a '–' symbol to indicate whether a certain cell fraction expresses or 
lacks a CD molecule. For example, a "CD34+, CD31–" cell is one that 
expresses CD34, but not CD31. This CD combination typically 
corresponds to a stem cell, opposed to a fully differentiated endothelial 
cell.  
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Two commonly used CD molecules are CD4 and CD8, which are 
generally used as markers for helper and cytotoxic T cells, respectively. 
When defining T cells, these molecules are defined in combination with 
CD3+, as some other leukocytes also express these CD molecules (some 
macrophages express low levels of CD4, dendritic cells express high 
levels of CD8). CD4 is also an essential receptor during HIV infection, 
allowing the HIV to bind to the helper T cell and destruction of CD4+ T 
cells. The relative abundance of CD4+ and CD8+ T cells is often used to 
monitor the progression of an HIV infection.  
It is important to note that while CD molecules are very useful in 
defining leukocytes, they are not merely markers on the cell surface. 
While only a fraction of known CD molecules have been thoroughly 
characterized, most of them have an important function. In the example 
of CD4 and CD8, these molecules are critical in antigen recognition (Zola 
et al., 2005). 
1.2.2.3 CD4: 
This molecules which was once called T4, is a specific receptor for 
MHC class 11 molecules. It is play a key role in the recognition of 
processed antigen by helper T cells. It is a 59-kDa glycoprotein found on 
helper T cells, thymocytes, and monocytes. CD4 is also a cell binding 
receptor for HIV (Tizard and Schubot, 2000).  
Helper T cells express T cell receptors (TCR) that recognize 
antigen bound to Class II MHC molecules. The MHC: antigen complex is 
also recognized by the helper cell’s CD4 co-receptor, which recruits 
molecules inside the T cell that are responsible for T cell's activation. 
Helper T cells have a weaker association with the MHC:antigen complex 
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than observed for killer T cells, meaning many receptors (around 200-
300) on the helper T cell must be bound by an MHC:antigen in order to 
activate the helper cell, while killer T cells can be activated by 
engagement of a single MHC:antigen molecule. Helper T cell activation 
also requires longer duration of engagement with an antigen presenting 
cell (Abbas et al., 1996). The activation of a resting helper T cell causes it 
to release cytokines that influence the activity of many cell types. 
Cytokine signals produced by helper T cells enhance the microbicidal 
function of macrophages and the activity of killer T cells (Alberts et al., 
2002).  In addition, helper T cell activation causes an upregulation of 
molecules expressed on the T cell's surface, such as CD40 ligand (also 
called CD154), which provide extra stimulatory signals typically required 
to activate antibody-producing B cells (McHeyzer-Williams  et al., 2006).  
1.2.2.4 CD8:  
 This 32-kDa dimeric glycoprotein which was once called T8 is 
specific receptor for MHC class 1 molecules found on cytotoxic T cells. 
It plays a key role in the recognition of endogenous antigen by these cells 
(Tizard  and Schubot, 2000) . 
Killer T cells are activated when their T cell receptor (TCR) binds 
to this specific antigen in a complex with the MHC Class I receptor of 
another cell. Recognition of this MHC: antigen complex is aided by CD8 
co-receptor on the T cell. The T cell then travels throughout the body in 
search of cells where the MHC I receptors bear this antigen. When an 
activated T cell contacts such cells, it releases cytotoxins that form pores 
in the target cell's plasma membrane, allowing ions, water and toxins to 
enter. This causes the target cell to burst, or to undergo apoptosis 
(NIAID, 2007). T cell killing of host cells is particularly important in 
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preventing the replication of viruses. T cell activation is tightly controlled 
and generally requires a very strong MHC/antigen activation signal, or 
additional activation signals provided by "helper" T cells (NIAID, 2007).  
1.2.2.5 CD4/CD8 Ratio: 
  This number is a reflection of the health of the immune system. 
The normal ratio is between 1 and 4. In HIV infection the CD4 count is 
often decreased and the CD8 count increased so the ratio might ‘invert’, 
that is become less than 1 (Mary et al., 2005). 
1.2.2.6 CD4 percentage: 
The proportion of all lymphocytes that are CD4 cells is called the 
CD4 percentage. In HIV-negative people, a normal result is 40%. Among 
HIV-positive people the CD4 percentage tends to decline as HIV disease 
progresses (Mary et al., 2005). 
1.2.3 Methods of CD4 and CD8 counts: 
1.2.3.1 Flow cytometry: 
The most common technique for measuring CD4 counts in 
developed country settings is flow cytometry. Flow cytometers use lasers 
to excite fluorescent antibody probes specific for various cell surface 
markers, such as CD3, CD4, and CD8, which distinguish one type of 
lymphocyte from another. 
 Rodriguez et al. (2005) emphasized, in their study in this issue the 
cost of a flow cytometer that ranges from $30,000 to $150,000, and the 
reagents needed for determining the lymphocyte surface markers by this 
method that are very costly. In addition, the use of flow cytometry 
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requires technical and operational expertise as well as a reliable 
electricity source. Considering all these factors together, it is no surprise 
that CD4 measurements by flow cytometry method cannot be widely 
applied in developing world settings. 
1.2.3.2 The Guava Easy CD4 System: 
Guava Technologies, Inc. has revolutionized CD4 counting technology 
with the introduction of the Guava Easy CD4 system. Guava's optimized 
system of reagents, software and instrument enables absolute CD4 counts 
to be performed quickly, easily and up to 20X more affordably than by 
other methods. The Easy CD4 system has been rigorously evaluated in 
comparison to established methods (i.e., conventional flow cytometry) for 
performing this assay and has been found to provide a result that is 
equivalent or even superior to those alternatives (Hayward, 2006). 
1.2.4 CD4 count in immunocompromised host: 
CD4 count is a marker of likely disease progression. Initially in 
HIV infection there is a sharp drop in the CD4 count and then the count 
levels off to around 500-600 cells (Mary et al., 2005)   
1.2.5 CD4 counts in non HIV infection: 
A normal CD4 count in a man without HIV infection will be 
approximately 400 to 1200 cells per cubic millimeter of blood, and 500 to 
1600 in women (Mary et al., 2005). 
The best CD4 count to give an accurate prediction for the future is 
the most recent count. Irregular counts (those unexpectedly high and low) 
may be laboratory errors or real temporary or sustained changes which 
should be checked for by repeating the count (Mary et al., 2005). 
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  In India, information on lymphocyte populations (T, B, and natural 
killer cells) and subpopulations (CD4 and CD8) is generally lacking 
(Uppal et al., 2003). Using flow cytometer method, they found that in 
normal Indian people  mean values of 2114 cells/ µl for total 
lymphocytes, 865 cells/ µl (40.2%) for CD4(+) lymphocytes, 552  cell ⁄µl 
(31.3%) for CD8(+) lymphocytes, and 1:7 for the CD4:CD8 ratio were 
recorded (Uppal et al., 2003). 
In China, mean values for CD4 and CD8 lymphocytes were 727 
and 540 cell ⁄ µl, respectively, yielding a CD4/CD8 ratio of 1.49. While 
CD8 lymphocyte values varied with age and gender, no significant 
differences in CD4 lymphocyte values were observed. Shanghai adults 
had approximately 100 fewer CD4 cell ⁄µl on average than Caucasians, 
suggesting that lower CD4 lymphocyte cutoffs for classifying and 
monitoring HIV infection may be needed in China (Jiang et al., 2004). 
In Turkey, the mean percentage and absolute values of the lymphocyte 
subsets were as follows: CD4:  1,095 +/- 391 cells /µl, CD8: 669 +/- 239 
cells /µl. The ratio of CD4/CD8 was 1.68 +/- 0.43 (Yaman et al., 2005). 
1.2.6 Total white blood cells: 
A white blood cell (WBC) count is used to investigate infections 
and unexplainable fever and to monitor treatments which can cause 
leucopenia (reduction in WBC count). The normal range of WBCs in 
adult of African origin is about 2600 – 8300 cell ⁄µl (Cheesbourgh, 2004). 
1.2.7 Differential counts of WBCs: 
A differential count of WBC provides information on the different 
white cells present in the circulating blood, i.e. neutrophils, lymphocytes, 
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monocytes, eosinophils, and basophils which are rarely seen. 
(Cheesbourgh, 2004). 
 
 
 
 
 
 
 
 
 
 
 
Table (3): White Blood Cell reference range :( Cheesbourgh, 2004). 
 WBC count 
Children at 1 year 6000 – 18000 
Children 4-7 years 5000 – 15000 
Adults 4000 – 10000 
Adults of African origin 2600 - 8300 
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Table (4): Differential WBC reference range in adults (Cheesbourgh, 
2004).   
40 -75% Neutrophils 
21 -40% Lymphocytes 
2 -10% Monocytes  
1 – 6% Eosinophils 
0 -1% Basophils 
  
 
1.1.8 Mycetoma in Sudan: 
It has been found in Sudan before the advent of modern medicine, 
by its present common name 'Nebit' meaning growth. Treatment by 
cautery and /or amputation was practice by 'Fakkis' during time of 
Mahdiya (1885-1899). A woman aged 70 years, who in 1930 reported to 
Khartoum Civil Hospital, gave a history of amputation in the lower third 
of her right leg. 
The Sudan seems to be the homeland of mycetoma .Lynch in 1964 
estimated the incidence of mycetoma in Sudan as 300-400 new hospital 
cases annually, this figure does not take into account the considerable 
number of Out patients and those seen at peripheral dispensaries where 
qualified doctors might not even be present . 
 There was a great need to establish a center to study a different 
aspect of Mycetoma and in response to this The Mycetoma Research 
Centre was establish in 1993 under the umbrella of the University of 
Khartoum, and hosted by Soba University Hospital, Khartoum- Sudan.  
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The strategies of the center are patient's treatment, conduction of 
research on mycetoma, training of medical and paramedical staff and 
provide the peripheral hospitals with trained medical staff. The centre is 
compromising of the following: male ward, female ward, laboratory, and 
library and out-patient clinic. 
In Sudan, M.mycetomatis accounts for 71.4% of all Mycetoma 
cases, S.somaliensis for 18%, A.madurae 5.3% A.pelletieri 2.7%, 
N.brasiliensis, C.iumata and A. nidulans for 2.6%. One case caused by A. 
flavus reported by Mahgoub (1973) and another caused by A.israeli   
(Mahgoub, 1985) both have been found in Sudan.  
 Mubarak (1991) reported that the majority of patients were from 
middle region and Khartoum 73.5%, Kordofan and Darfour 17.3%, North 
region 7.4% and only 7 patients were from East region, while Fahal 
(1995) reported that most of the eumycetoma patients were from Middle 
states and common causative agent was Madurella mycetomatis, while in 
patients with actinomycetoma infection, most of them were from Middle 
states (33%) and Khartoum (31%) and common causative agent was 
Streptomyces somaliensis.  
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Table (1): Cases of mycetoma in Sudan between 1971- 1975 
(Mahgoub, 1977). 
YEAR NO. OF CASES 
1971 210 
1972 377 
1973 428 
1974 378 
1975 431 
 
 
Table (2): Sites of mycetoma in different studies.   
Site Sudan 
(Mahgoub and 
Murray 1971). 
Senegal West 
Africa (Ray 
1961). 
Mexico 
(Gonzalez-
ochoa 1962). 
Foot 68.8% 68% 35% 
Leg 3.2 10% 28% 
Knee 4.4% 4% - 
Thigh 2% 3% - 
Buttocks and 
perineum  
2% 3% 1% 
Arm 3.8% 3% 8% 
Hand 10.7% 5% 2% 
Chest wall 1%  1% 2o% 
Head and neck 3.1% 2% 3% 
Abdominal wall 1% 1% 3% 
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Chapter Two 
Materials and Methods 
Clinical Investigations: 
2.1 Survey: 
Questionnaire was used to collect information including: name, 
sex, age, marital status, and residence, history of the disease, numbers of 
lesions, type of mycetoma, duration and treatment from 49 mycetoma 
patients. 
The group surveyed included: infected untreated or new patient (17 
individual), infected treated patient (32 individual) and normal control 
group (16 individuals). 
2.2 Collection of samples: 
A total of 49 blood samples were collected from Mycetoma 
patients in Mycetoma Research center – Soba Civil Hospital and Estac 
National Laboratory - Khartoum state between December 2002 and 
February 2003. 
Venous blood samples were collected using vacutainers and 
needles (syringes (5ml). The blood was drawn into the tube which 
contained anticoagulant (EDTA), then placed in cold box below at 4ºC 
and transported to The Institute of Endemic Disease, Faculty of Medicine, 
University of Khartoum. The blood was examined by Dynalbeads T4-T8 
Quantitative Method. 
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2.2.1 Storage of samples: 
All samples were stored after collection in a cold box below 4ºC and were 
examined within 24 hours.   
2.3 Dynalbeads T4-T8 quantitative method: 
2.3.1 Material provided: 
1- Syringes. 
2- Gloves. 
3- EDTA vacutainers. 
4- Cold box. 
5- Improved Neubauer ruled counting chamber (heamocytometer).  
6- A manual counter. 
7- Buffer solution (PBS). 
8- Dilution fluid (df). 
9- Crystal violet. 
10- - Leishman stain 
11- Light microscope  
2.3.2 Dynalbeads material: 
1- Dynal magnetic particle. 
2- Magnetic beads coated with anti-CD14 antibody. 
3-  Anti-CD4 monoclonal antibody. 
4- Anti-CD8 monoclonal antibody. 
5- Dynal rotator. 
6- Lyses reagent.  
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2.3.3 Storage of dynalbeads: 
All components were stored in a refrigerator below 4ºC, after used 
all components were immediately returned to the refrigerator  to avoid 
damage of contents.  
2.3.4 Technique:  
Dynalbeads T4-T8 Quantitative Method was used to count CD4, CD8 T- 
lymphocytes of whole blood in mycetoma patient. 
2.3.4.1 Principles of the Technique:  
Dynalbeads T4-T8 Quantitative Method is an immunomagnetic cell 
isolation method which uses Dynabeads magnetic particles coated with 
antibodies to CD4 and CD8 antigens to capture and isolate CD4¯and 
CD8¯ T lymphocytes from whole blood. 
2.3.4.2 Procedure:  
The counts were carried out within 1 hour after addition of lyses reagent. 
The batch size examined was not more than 6 samples each time. 
1- The collected blood was put in Dynal rotator for 2min. 
2- Two hundred and five µl of whole EDTA anti-coagulated blood were 
added to 225µl of buffer solution PBS.  
3- Twenty five µl of magnetic beads coated with anti-CD14 antibody (for 
monocyte depletion) were added and the mixture was incubated for 10 
min at room temperature in Dynal rotator, and 2min in Dynal magnetic 
particle. 
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4- Two aliquots 200µl were taken from each supernatant of the 
monocyte-depleted blood and dispensed into two tubes each containing 
200µl of buffer solution PBS. 
5- Twenty five µl of beads coated with anti-CD4 monoclonal antibody 
were added to one tube, and a similar volume of anti-CD8 coated beads to 
the other tube.  
6-The tubes were incubated at room temperature in Dynal rotator for 10 
min, and for 2 min in Dynal magnetic particle, and washed with 500µl 
PBS, put in the Dynal magnetic particle and then washed again with 
500µl PBS.  
7- Fifty µl of lyses reagent was added to each tube mixed and left for 
5min. 
8- The isolated CD4+ and CD8+ T lymphocytes were stained by addition 
of fifty µl of crystal violet to each tube.  
9- The stained nuclei were counted in a heamocytometer using an 
ordinary light microscope and results were expressed as cells per 
microlitre of whole blood.  
W*10 ⁄ 2=Cell⁄ µl 
W=∑ cells in the 4 squares of heamocytometer. 
2.4 Total White Blood Cells count (TWBCs): 
Dilution fluid (df) contained: 
1- 2% Glaial acetic acid. 
2- 98% distiled water. 
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3- Methylene blue. 
2.4.1 Procedure: 
 Dilution fluid (0.38ml) was added to 0.02 ml of well-mixed 
EDITA anticoagulated venous blood sample, mixed and by capillary tube 
one of the grid of the heamocytometer was filled, left for 2 min, dried and 
examined under light microscope using 10x objective. TWBCs were 
counted in four large squares of heamocytometer marked W1, W2, W3 
and W4 (Figure,  ). Results were expressed as cell ⁄lµ. 
W*50=cell ⁄µl 
W=∑cells in 4 squares of heamocytometer.        
2.5 Differential counts of TWBCs: 
Thin films were prepared from well-mixed EDITA anticoagulated 
venous blood samples, stained with Leishman stain, left for 5 min, 
washed with buffered water pH 6.8, left for 5 min to dry and then 
examined under light microscope. The number of neutrophils, 
eosinophils, lymphocytes and monocytes were counted and the 
numbers were expressed as percentage (%). 
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Fig. (1): Dyna  magnetic beads used for separtion of cells using specific 
mAb. 
 
 
 
 
Fig. (2):   The dynale magnetic particle to separate dynabeads coated 
lymphocyte. 
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Fig. (3): Separating cells: the target-bead complexes will migrate to the 
tube-side adjacent to the magnet. 
 
 
 
Fig. (4): Washing the target-bead complexes in the dynale magnetic 
particle. 
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Fig. (7): Improved Neubauer ruled counting chamber (Cheesbourgh, 
2004). 
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Chapter Three 
Results 
A total of 49 blood samples were collected from mycetoma 
patients in Mycetoma Research Center – Soba Civil Hospital and Estac 
National laboratory - Khartoum State between December 2002 and 
February 2003. The group surveyed included: 17(34.7%) infected 
untreated or new patient, 32 (65.3%) infected treated patients, and normal 
control group (16 individual). 
3.1 Sex: 
  Male were 39 (79.6%) and 10 (20.4%) were female, and male to 
female ratio was 4:1 (Table, 5).   
3.2 Age: 
 Twelve patients (26.7%) were in age group 21 – 25 years; this was 
the most predisposed group of age. The next group of age was 15 – 20 
years in which 11 (22.4%) individuals were infected (Table, 6). 
3.3 Occupations: 
 Many patients were students 10(20.4%), while jobless were 
9(18.4%) and farmers were 8 (16.8%) (Table, 7). The majority of the 
jobless were male 8 (88.9%) while 1 (11.1%) was a female, and all the 
farmers were male.  
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Table (5): Males and females infected by mycetoma. 
Percentage % Number infected Sex 
79.6 % 39 Male 
20.4 % 10 Female 
100 % 49 Total 
 
 
 
 
 
  
 
Table (6): Age groups of mycetoma infected patients. 
Age (Years) Number infected Percentage (%) 
15_20 11 22.4  
21_25 12 26.7 
26_30 8 16.3  
31_35 3 6.1  
36_40 8 16.3  
41< 7 14.3 
Total 49 100% 
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Table (7): Occupations of mycetoma patients. 
Occupation No. 
infected 
Percentage (%) 
Jobless 9 18.4 
Student 10 20.4  
Driver 1 2.0  
Housewife 4 8.2 
Farmer 8 14.3 
Merchant 6 12.2  
Laborers 6 12.2  
Teacher 1 2.0  
Butcher 1 2.0  
Painter 1 2.0  
Soldier 2 4.1 
Total 49 100% 
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3.4The incidence of the disease: 
 Algazira state was the most infected state (Table, 8), where 17 
(34.7%) mycetoma patients were diagnosed, and 12(70.6%) of them were 
male and 5 (29.4%) were females. The next state was Khartoum state 
where 8 (16.3%) mycetoma patients were diagnosed followed by North 
Kordofan state where 8 (16.3%) mycetoma patients were diagnosed. 
Fourteen (82.4%) of all patients in Algazira state, had eumycetoma 
infection and 3 (17.6%) patients had actinomycetoma infection, and the 
site of infection was the left foot in 7 (41.2%) patients and right foot in 6 
(15.2%) patients.  
3.5 Duration: 
 The duration of the disease varied from 7 month to 30 years. The 
majority of patients 22(44.9%) had duration varied from 7 month to 3 
years (Table, 9) and most of them 7(14.3%) were within the age group 15 
– 20 years old. Eighteen (81, 8%) of patients were male and 4(18.2%) 
were female. One case reported with duration 30 years. 
3.6 Modes of onsets: 
  There were 36(73.5%) patients had the disease not known to be 
preceded by trauma, 9(18.4%) patients following injury (injurious agent 
not specific), 3(6.1%) patients by wood trauma and only one patient (2%) 
had the disease by thorn prick (Table, 10).  
3.7 Family history: 
 Most of the patients 41(83.7%) had no family history of mycetoma 
infection, 36 (73.4%) were male and 5 (10.2%) were females. Eight 
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(16.3%) patients had one or more people in their family had mycetoma 
infection (Table, 11). 
3.7 Sites of infection: 
3.7.1 Patients with single lesion: 
There were 46 (93%) patients who had a single lesion (Table, 12). 
Left foot was the main site of infection in 17 (34.7%); followed by the 
right foot 14 (28.6%). There was 1(2%) patient with mycetoma in the 
right hand and 1(2%) patient in left hand and one with infection in the 
right site of the back. 
3.7.2 Patients with multiple lesions: 
 There were 3 (6.1%) patients who had mycetoma infection in more 
than one site. Two cases of the eumycetoma infections, one had 
infections in three sites, right hand, right leg and foot, the other case in 
right foot and thigh. One case of actinomycetoma infection found in the 
left foot, dorsum and middle aspects. 
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Table (8): Geographical distributions of mycetoma infected patients.
   
State No. 
infected
Percentage% 
Algazerah 16 32.7  
Khartoum 8 16.3 
Sinar 3 6.1 
AlGadarif 1  2.0 
Blue Nile 2 4.1 
River Nile 1 2.0 
White Nile 4 8.2  
N.Kordufan 8 16.3  
S.Kordufan 1 2.0 
W.Darfour 2 4.1 
S.Darfour 3 6.1 
Total 49 100% 
 
 
 
 
Table (9):  Duration of symptoms in mycetoma patients. 
Duration 
(years) 
Number infected Percentage (%) 
7month _3years 22 44.6 
4 _ 7 8 16.3 
8 _ 11 8 16.3 
12 _ 15 4 8.2 
16 _ 19 3 6.1 
20 -24 3 8.2 
25< 1 2.0 
Total 49 100% 
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Table (10): Mode of onsets of mycetoma infection. 
 
Mode of onsets No. infected Percentage (%) 
Not known to be preceded by 
trauma 
36 73.5 
Following injury (injurious 
agent not specified) 
9 18.4 
Wood trauma 3 6.1  
Thorn prick 1 2.0  
Total 49 100% 
 
 
 
 
  
 
Table (11): History of the disease in families of mycetoma patients.
     
Family history Number infected Percentage (%) 
With history 8  16.3  
Without history 41  83.6  
Total 49 100% 
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Table (12): Site of lesions in mycetoma patients. 
         
Site Number infected Percentage% 
Left foot 17 34.7  
Right foot 14 28.6 
Thigh 2 6.1  
Right leg 2 4.1  
Left leg 2  4.1 
Right knee 2  4.1 
Left knee 1 2.0  
Right hand 1 2.0  
Left hand 1 2.0  
Head and neck 2 4.1 
Right eye 1 2.0  
Back 1 2.0  
Multiple lesions 3 3.1 
total 49 100% 
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3.8 Type of mycetoma: 
 More than half of the patients 29 (59.2%) had eumycetoma, 
whereas 19 (38.8%) patients had actinomycetoma infections and 1(2%) 
case had not yet diagnosed (Table, 13). In eumycetoma patients the male: 
female ratio was 6.5:1, while in actinomycetoma it was 2:1 and there was 
one case of A.pellerie. 
3.9 Treatment: 
 In this study, all eumycetoma patients were treated by 
ketoconazole (200 mg per\day) and folic acid and 11(22.4%)   
actinomycetoma infected patients were treated by combination of 
streptomycin, septrin and folic acid (S.S.F) while one patient had Septrin, 
Penicillin and Folic acid (S.Pen.F) and one patients was given Dapsone . 
One eumycetoma new patient had Cephaloxin tablets (500mg) for 
treatment of pus, and other eumycetoma new patient had previous 
treatment with Ampiclox tablets one week earlier and he had surgery 3 
days ago before sample was taken (Table, 14). 
3.10 Total white blood cells counts:   
Eleven (24.5%) had WBCs counts of 4050 – 5000cell⁄µl and 
10(20.4%) patients had WBCs counts 5050 – 6000cell⁄µl. Two patients 
with massive lesions and discharge sinuses, had counts of more than 
10050cell⁄µl (Table, 15). 
3.11 CD4 and CD8 counts: 
  Fourteen (28.5%) patiens had CD4 counts between 505- 
700cell⁄µl, 11(22.45%) patients had 305 – 500cell⁄µl and 11(22.45%)   
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patients had 705 – 900cell⁄µl CD4 counts (Table, 16).  The mean value of 
CD4 counts of all patients was 626.9cell⁄µl.  
Twelve (25.5%) patients had CD8 counts between 310 - 500cell⁄µl, 
while 10(20.4%) patients had 710 - 900cell⁄µl (Table, 17). The mean   
value of CD8 counts for all patients was 706.6cell⁄µl (Table, 22,23). 
3.12 White blood cells, CD4 and CD8 counts in infected untreated 
mycetoma patients: 
 Four (23.5%) out of 17 untreated mycetoma patients had TWBCs 
counts between 4050 - 5000cell⁄µl and one case had count of 10050cell⁄µl 
(Table, 18). Six (35.3%) patients had CD4 counts between 305 -
500cell⁄µl (Table, 19). Six (35.3%) untreated patients had CD8 counts 
310 - 500cell⁄µl and 5 cases had count of more than 1100cell⁄µl as shown 
in table (20). 
3.13 White blood cells, CD4 and CD8 counts in infected treated 
mycetoma patients: 
 Seven (21.9%) out of 32 infected treated patients had TWBCs 
count between 4050 – 5000cell⁄µl and 7(21.9%) patients had 5050 - 
6000cell⁄µl (Table, 21). Nine (28.1%) patients had CD4 counts between 
505 - 700 cell⁄µl and one case had more than 1105cell⁄µl counts as shown 
in table (22). Eight (25%) patients had CD8 counts 710 - 900cell⁄µl and 
7(21.9) cases showed more than 1000 cell ⁄µl (Table, 23).  
3.14 White blood cells, CD4 and CD8 counts in non – infected 
controls: 
 Seven (43.75%) out of 16 control individuals had TWBCs count 
between 3000 – 5000cell⁄µl and 1(6.25%) patient had more than 10000 
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cell⁄µl (Table, 24). Six (37.5%) individuals had CD counts between 820 – 
1000 cell⁄µl, 4 (25%) had CD4 counts more than 1220 cell⁄µl and 
1(6.25%) had CD 4 counts between 620 – 800 cell⁄µl (Table, 26). Eight 
(50%) individuals had CD8 counts between 610 – 800 cell⁄µl, 5(31.25%) 
had CD8 counts between 400 – 600 cell⁄µl and 3 (18.75%) had CD8 
counts between 810 – 1000 cell⁄µl.  
3.15 CD4⁄CD8 ratio:  
 The CD4⁄CD8 ratio in all mycetoma patients was (1:1). In new and 
treated patients the ratio was (1: 2) while in non- infected controls it was 
(1.6:1) (Table, 30). 
3.16 Differential counts of white blood cells: 
 Over all mycetoma patients the mean value of neutrophils was 
57%, lymphocytes 38%, monocytes 3% and eosinophils 2% (Figure, 10). 
In untreated mycetoma patients the mean value of neutrophils was 59%, 
lymphocytes 38%, monocytes 2% and eosinophils 1%, while in treated 
patients the mean value of neutrophils was 55%, lymphocytes 40%, 
monocytes 3% and eosinophils 2%. In controls individuals the mean 
value of neutrophils was 58%, lymphocytes 39%, monocytes 2% and 
eosinophils 1%. (Table, 31). 
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Table (13): Types of mycetoma infection.      
Type of mycetoma Number infected  Percentage (%) 
Eumycetoma 29 59.2% 
Actinomycetoma 19 38.8% 
Not yet  diagnosed 1 2.0   
Total 49  100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table (14): Drugs used for treatment of mycetoma infections.  
 
Drug Number of patients  Percentage (%) 
Dapson 1  2.0 
Keto+folic 17 34.7 
S.S.F* 12 2.8 
S.pen.F 1  2.0 
Ampiclox 1 2.0 
New patient 17  30.6 
Total 49 100% 
Keto: ketoconazole. 
S.S.F: streptomycin, septrin and folic acid. 
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Table (15): Range of Total white blood cells counts of mycetoma 
patients. 
TWBCs counts No. of patients Percentage% 
2000-3000 1 2.04  
3050-4000 4 8.2 
4050-5000 11 24.5 
5050-6000 10 20.4  
6050-7000 4 6.1  
7050-8000 6 12.2  
8050-9000 5 10.2  
9050-1000 3 6.1  
10050< 2 4.1 
Missed 3 6.1  
Total 49 100% 
 
 
Table (16): Range of TWBCs counts of infected untreated and 
treated mycetoma patients. 
 
 
 
 
 
 
 
 
TWBCs
No. of 
untreated 
patients 
  (%) 
TWBCs
 counts
No. of 
treated 
patients 
  (%) 
3050-4000 2 11.8 2000-3000 1 3.1 
4050-5000 4 23.5 3050-4000 2 6.3 
5050-6000 3 17.6 4050-5000 7 21.9 
6050-7000 3 17.6 5050-6000 7 21.9 
7050-8000 1 5.9 6050-7000 1 3.1 
8050-9000 3 17.6 7050-8000 5 15.6 
10050< 1 5.9 8050-9000 2 6.3 
Total 17 100% 9050-10000 3 9.4 
  10050< 1 3.1 
  Missed 3 9.4 
  Total 32 100% 
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Table (17): Range of  TWBCs counts of non- infected controls: 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table (18): Differential counts of untreated, treated mycetoma 
patients and non – infected control:  
 
 
Eosinophils
 
Monocytes  
 
lymphocytes  
 
Neutrophils 
  
 
Group  
1%  2%  36%  59%  Untreated 
patients  
2%  3%  40%  55%  Treated 
patients  
1%  2%  39%  58%  Controls   
 
 
 
 
 
 
TWBCs counts No.     (%) 
3000 – 5000 7 43.75  
5055 – 7000 4 25.00  
7050 – 10000 4 25.00  
10050 -  1 6.25  
Total 16 100% 
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Table (19): Range of CD4 and CD8 T lymphocytes count of 
mycetoma patients. 
 
      
CD4 
count 
No. of 
patients 
Percentage 
(%) 
CD8 
 count 
No. of 
patients. 
Percentage 
% 
100-300 5 10.2  100-300 8 16.3  
305-500 11 22.4  310-500 12 24.5 
505-700 14 28.5 510-700 7 14.3 
705-900 11 22.4  710-900 10 20.4  
905-1100 5 10.2  910-1100 2 4.1 
1105< 3 6.1  1110-1300 3 6.1  
Total 49 100% 1310-1500 3 6.1  
   1510< 4 8.2 
   Total 49 100% 
 
 
 
Table (20): Range of CD4 and CD8 counts of infected untreated 
mycetoma patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD4 
counts
No. of 
untreated 
patients 
  (%) 
CD8 
counts
No. of 
untrea
ted 
patient
s. 
 % 
100-300 1 5.9  100-300 2 11.8 
305-500 6 35.3  310-500 6 35.3 
505-700 3 17.6  510-700 3 17.6 
705-900 4 23.5  710-900 1 5.9 
905-1100
1 5.9  910-
1100
1 5.9 
1105<
2 11.8  1110-
1300
1 5.9 
Total
17 100% 1310-
1500
2 11.8 
  1510< 1 5.9 
  Total 17 100 
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Table (21): Range of CD4 and CD8 counts of infected treated 
mycetoma patients. 
 
CD4 counts
No. of 
treated 
patients 
  (%) 
CD8 
counts
No. of 
treated  
patients 
  (%) 
100-300 4 12.5  100-300 5 15.6 
305-500 7 21.9  310-500 7 21.9 
505-700 9 28.1  510-700 5 15.6 
705-900 7 21.9  710-900 8 25.0 
905-1100 4 12.5  910-1100 1 3.1 
1105< 1 3.1  1110-1300 3 9.4 
Total 32 100% 1310-1500 1 3.1 
  1510< 2 6.3 
  Total 32 100 
 
  
 
 
 
 
 
 
 
 
 
Table (22): Range of CD4 and CD8 counts of non- infected controls: 
 
CD4 counts No.     (%) CD8 
counts 
No.     (%) 
400 - 600 3 18.75  400 – 600 5 31.25 
620 – 800 1 6.25 610 – 800 8 50.0 
820 – 1000 6 37.5 810 – 1000 3 18.75 
1020 – 1200 2 12.5 Total 16 100% 
1220 -  4 25.0    
Total  16 100%    
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Table (23): CD4/CD8 ratio in untreated, treated mycetoma patients 
and non – infected control: 
 
Non-infected 
control  
Treated 
patients  
Untreated 
patients  
Group  
1.6:1  1.2:1  1.2:1  Ratio   
 
 
 
 
 
 
 
Table (24): White blood cells, CD4 and CD8 counts of infected 
untreated mycetoma patients compared to non-infected controls. 
parameter Non-
infected 
(n = 16)  
 infected-
untreated 
(n=17) 
SE Probability*
TWBCs 5709a 6081a 691 0.594 
CD4 1010a 664b 123 0.009  
CD8 639a 1378a 769 0.344 
*Mean values have different superscript letters within each raw differ 
significantly at p ≤ 0.05. 
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Table (25): White blood cells, CD4 and CD8 counts of infected-
treated mycetoma patients compared to non-infected controls. 
parameter  non-
infected 
(n = 16)  
 infected- 
treated 
(n=32) 
SE Probability*
TWBCs 5709a 6331a 663 0.354 
CD4 1010a 710a 181 0.116 
CD8 639a 719a 112 0.478 
*Mean values have different superscript letters within each raw differ 
significantly at p ≤ 0.05. 
 
 
 
 
 
 
 
 
Table (26): White blood cells, CD4 and CD8 counts of infected-
untreated mycetoma patients compared to infected – treated patients.  
 
parameter infected 
untreated 
(n = 17)  
infected- 
treated 
(n=32) 
SE Probability*
TWBCs 6081a 6331a 642 0.699 
CD4 664a 710a 167 0.745 
CD8 1378a 719a 548 0.235 
*Mean values have different superscript letters within each raw differ 
significantly at p ≤ 0.05. 
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Figure (10): Differential counts of white blood cells of mycetoma 
patients. 
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Fig.(8): Normal blood film showing from left to right a monocyte, 
large lymphocyte and neutrophils (Cheesbourgh, 2004). 
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Fig.(9): Esinophil in normal blood film (Cheesbourgh, 2004). 
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Chapter Four 
 
Discussion 
          
 Mycetoma could be one of the most important diseases in Sudan. 
The climate, the soil and nature of economic which is depends on 
agriculture, makes infection of people especially young and youth, 
possible, this increases the number of non effective citizens. Thus, it is so 
important to do such research to find some ways to fight mycetoma and 
protect the farmers, and all other occupations from being infected and to 
study the effectiveness of treatment.   
A total of 49 blood samples were collected from mycetoma 
patients in Mycetoma Research Center – Soba Civil Hospital and NIPH 
National laboratory - Khartoum State between December 2002 and 
February 2003. The group surveyed included: 17(34.7%) infected 
untreated or new patient, 32 (65.3%) infected treated patients, and normal 
control group (16 individual). 
 In this study, males were dominant, male were (79.6%) and 
(20.4%) were females, and male to female ratio was 4:1. These findings 
are in agreement with Abbott (1956) who studied mycetoma in Sudan and 
reported that male to female ratio was 5:1. In eumycetoma patients the 
ratio was 6.5:1, while in actinomycetoma it was 2:1, these findings 
disagree with Fahal (1995) who reported that in eumycetoma patients it 
was 4:1 and in actinomycetoma it was 2.7:1. 
   The studied patients were used between 15 to 70 years old, most 
of them (26.7%) were in the age group 21-25 years and 22.4% of the 
patients were in the age group 15-20 years. There was one case of 70 
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years old. This prevalence agrees with those of Develoux et al. (1988), 
Agarwal et al. (1985) and Basset et al. (1965). They reported that 
mycetoma affected adults between 20 – 40 years old and cases are found 
in children as well as elderly. 
 In this study, students (20.4%) were the most predisposed 
occupation. Next came the jobless (18.4%) and then farmer (14.3%). This 
findings are in agreement with Fahal (1995) who reported that students 
were the majority of patients (30.2%)   followed by farmers (14%).  Also 
other outdoor occupations (soldier, painter, butcher…etc) were found 
infected in this study (20.4%). This agree with Mubarak (1991) who 
found that 44.2% of mycetoma patients had outdoor activities. 
 The geographical distributions of the disease in Sudan showed high 
prevalence in Algazerah State (34.7%) and Khartoum State (16.3%) and 
cases were reported in Kordufan and Darfur (28.6%). This result agrees 
with the findings of Mubarak (1991) who reported that the majority of 
patients were from middle region and Khartoum State (73.5%) and cases 
were reported in Kordufan and Darfur (17.3%). However, this study 
noted some cases in River Nile, Sinar, Blue Nile and White Nile which 
supported the strong relation between the disease and agricultural areas. 
The results showed that the duration of the disease varied from 
7month to 30 years and this in agreement with Mahgoub and Murray 
(1973), Bocarro (1909) and Singh (1978), who reported that the duration 
of the disease started from three months to 30 years, but Fahal (1995) 
reported the duration to be varied from 3month to 50 years. 
Mode of onsets in majority of patients in this study (73.5%) was 
not known to be preceded by trauma, this is in agreement with Mahgoub 
63 
 
and Murry (1973), Abbott (1965) and Lynch (1964). These authors stated 
that in many patients there is no history of trauma at the site of infection. 
Fahal (1995) also reported that majority of patients (65%) were not sure 
of such history. 
This study illustrated that most of patients (83.7%) had no history 
of disease in their families and the majority of them were males (73.4%). 
None the less 16.3% patients had one or more people in their families had 
mycetoma infection. These results established that mycetoma disease is 
not transmitted from person to person. Previous research proved the 
disease is not contagious from person to other or from animal to human 
(Mahgoub and Murray 1973; Abbott, 1965; Lyunch, 1964). 
Study of the sites of infection revealed that the left foot was the 
major site of infection (34.7%), followed by the right foot (28.6%). These 
findings confirm the results of Mahgoub and Murray (1973), Magana 
(1984), Abbott (1965) and Fahal et al. (1992) who reported that the 
commonest site for mycetoma was the foot which accounts for 70% of 
cases and for unexplainable reasons the left foot was the mostly affected. 
Second sites were left leg (4.1%), right leg (4.1%) and right knee (4.1%), 
while third site was left knee (2.0%), left hand (2.0%) and right hand 
(2.0%). However, these findings disagree with Mahgoub (1985) and 
Tight and Bartlell (1981) who reported that the hand was the second site 
in 12% of the cases. Abbott (1954) and Mogharaby (1967) reported   that 
the leg was the second site, and the hand was the third site of infection. 
There were 6.1% of the patients who had mycetoma infection in 
more than one site. Fahal (1995) reported that 4.4% had more than one 
lesion at different sites, whereas Mubarak (1991) reported that 2.4% had 
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double lesions. These findings revealed that mycetoma commonly infect 
one site of the body but in few patients it may infect more than one site. 
In this study, more than half of the patients (59.2%) had 
eumycetoma, whereas 38.8% of the patients had actinomycetoma 
infections and there was one case of Nocardia spp. and one case of 
A.pellerie, and one case (2%) had not yet be  diagnosed. Mahgoub (1985) 
reported that in Sudan, M.mycetomatis (eumycetoma) accounts for 71.4% 
of all mycetoma casesand that, S.somaliensis for 18%, A.madurae for 
5.3% A.pelletieri (actinomycetoma). Further Fahal (1995) reported that 
most of the patients had eumycetoma infections and the common 
causative agent was Madurella mycetomatis. These findings in addition to 
the present ones confirm that eumycetoma was the dominant type of 
mycetoma infection in Sudan. 
 The drug used in all eumycetoma patients (34.7%) was 
ketoconazole (200 mg per\days) with folic acid. Mahgoub and Gumaa 
(1984) reported that in cases of eumycetoma due to M.mycetomatis the 
drug of choice was ketoconazole and patients with actinomycetoma  used 
combination of Streptomycin, Septrin and Folic acid (S.S.F) and only one 
patient used Dapson.  However, Mahgoub (1985) recomended that in 
patients with actinomycetoma infection the standard treatment is a 
combination of streptomycin and cortrimoxazole, but if there is no 
response, a combination of streptomycin with one of the following drugs 
are given dapsone, sulphadoxine-pyrimethamine, fansidar and rifampicin.  
Total white blood cells counts in majority of  mycetoma patients 
(24.5%)  was between 4050 – 5000 cell⁄ µl and 20.4% of patients had 
WBCs counts of 5050 – 6000 cell⁄ µl. These counts are similar to counts 
in non- infected controls and within the normal range of WBCs in adults 
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of African origin. Cheesbourgh (2004) reported that WBC count of about 
2600 – 8300 cell ⁄µl is normal for adult African persons. But, there were 
two patients who had counts more of than 10050 cell ⁄µl, this may be due 
to massive lesions and that many discharging sinuses were noted in these 
two patients. 
  The mean value of differential counts of white blood cells for all 
mycetoma patients' neutrophils was 57%, lymphocytes 38%, monocytes 
3% and eosinophils 2% (Figure, 10). In untreated patients the mean value 
of neutrophils was 59%, lymphocytes 36%, monocytes 2% and 
eosinophils 1%, while in treated patients the mean value of neutrophils 
was 55%, lymphocytes 40%, monocytes 3% and eosinophils 2%.In non- 
infected control the mean value of neutrophils was 58%, lymphocytes 
39%, monocytes 2% and eosinophils 1%. 
  Cheesbourgh (2004)   reported that the normal range in adult's 
neutrophils were 40 -75%, lymphocytes 21 -40%, monocytes 2 -10% and 
eosinophils 1 – 6%. Hence, the differential counts reported in the present 
investigations are within the normal range, and not different from those 
non - infected control. 
One third of the patients (28.5%) had CD4 counts between 505- 
700 cell⁄µl, and the mean value of CD4 counts of all patients was 626.9 
cell⁄µl. The mean value of CD4 counts in treated patients was 606.8 
cell⁄µl and in untreated patients it was 664.7 cell⁄µl whereas in non- 
infected control individuals it was 1010 cell⁄µl, These values are within 
the normal ranges. Mary et al. (2005) reported that a normal CD4 count 
in a man without HIV infection will be approximately 400 to 1200 cell/ 
µl. Uppal et al. (2003) studied normal Indian people and found that the 
mean value of CD4 counts were 865 cell⁄µl. Jiang et al. (2004) studied 
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normal Chinese people and reported that the mean values for CD4   
lymphocytes was 727 cell ⁄µl, while in Turkish people; Yaman et al. 
(2005) showed that the mean value of  CD4 counts was 1,095 +/- 391 cell 
⁄µl. Mary et al. (2005) reported that there was a sharp drop in the CD4 
count in HIV infection and then the count levels off to around 500-600 
cells.   
The CD4 T lymphocytes counts of infected untreated mycetoma 
patients in the current investigation was significantly low when compared 
with CD4 count of non-infected control (Table, 27), but numerically 
lower than CD4 counts of infected treated patients (Table, 29). This 
indicates that mycetoma infection may decrease the CD4- T lymphocytes 
count and that treatment may elevate this effect. The confirmation of 
these findings warrants further investigation. 
CD8+ cells in one quarter of patients (25.5%) had counts between 
310 – 500 cell ⁄µl and the mean value of CD8 counts for all patients was 
706.6 cell ⁄µl. The mean value of CD8 counts in treated patients was 
720.9 cell ⁄µl and in untreated patients it was 679.7cell⁄µl while in control 
individuals it was 639.1 cell ⁄µl. Uppal et al. (2003) studied normal Indian 
people and found CD8 counts were 552 cell ⁄µl. Jiang et al. (2004) 
studied normal Chinese people and reported that the mean values for CD8 
lymphocytes were 540 cell ⁄µl, while in normal Turkish people; Yaman et 
al. (2005) showed that CD8 counts were 669 cell ⁄µl.  
The CD8 mean counts of infected untreated (1378 cell ⁄µl), 
infected treated (719 cell ⁄µl) and non- infected control (639 cell ⁄µl) in 
this study were higher than the value reported by Uppal et al. (2003) and 
Jiang et al. (2004), but nearly similar to value reported by Yaman et al. 
(2005). The statistical analysis also showed that there was no significant 
67 
 
differences in CD8 – T lymphocytes count between the three groups 
(Tables,27 ,28 , 29). None the less, counts in infected untreated (1378 cell 
⁄µl) was numerically higher than infected treated (719 cell ⁄µl) and non- 
infected control (639 cell ⁄µl)     
 The numerically high value of CD8 counts in untreated patients 
(1378 cell ⁄µl) when compared to non- infected control (639 cell ⁄µl) or 
infected treated patients (719 cell ⁄µl) indicate that mycetoma infection 
may increase CD8 T lymphocyte counts and treatment decrease the CD8 
counts of mycetoma infected patients. This observed effect of infection 
and treatment on CD8 counts of mycetoma patients required further 
studies.    
Results of this study showed that CD⁄CD8 ratio was 1.1:1 for all 
patients. The CD4⁄CD8 ratio was (1.2:1) in treated and untreated patients 
while in normal person it was (1.6:1).   Uppal et al. (2003) studied normal 
Indian people and found CD4:CD8 ratio was 1:7 while Jiang et al., 
(2004) studied normal Chinese people and reported that the CD4/CD8 
ratio was 1.4. 
Mahgoub (1977) found defective T-Cell mediated response 
especially in those patients who were not responding to the treatment. So 
it was concluded that mycetoma causes deficiency in cell mediated 
immune response (Magoub et al., 1977). The finding was supported by 
the fact that eumycetoma could be induced in naturally athymic mice but 
not in normal mice (Mahgoub, 1981). 
This investigation used CD4 and CD8 as markers for helper and 
cytoxic T-lymphocyte respectively. The investigation illustrated that there 
was significant decrease in CD4 counts when infected - untreated 
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mycetoma patients were compared with non – infected controls and 
numerically lower CD4 counts of infected treated patient (664 cell ⁄µl vs. 
710 cell ⁄µl). The CD4 counts of infected treated patient were numerically 
lower when compared with non-infected controls (710 cell ⁄µl vs. 1010 
cell ⁄µl). This indicates that mycetoma infection has adverse effect on 
CD4+ T lymphocyte counts. The investigation also revealed that the CD8 
counts of infected untreated mycetoma patient was numerically higher 
than non-infected control (1378 cell ⁄µl vs. 639 cell ⁄µl) and infected 
treated patients (1378 cell ⁄µl vs.719 cell ⁄µl). The CD8 counts of treated 
patient were less numerically higher when compared with non infected 
controls (719 cell ⁄µl vs. 639 cell ⁄µl). This indicates that mycetoma 
infection elevated CD8 counts both in untreated and treated mycetoma. 
The observed significant decrease in CD4+ count  and numerical 
increase in CD8+ T-Lymphocyte counts in mycetoma untreated patients 
do give an explanation to previous reports of Mahgoub (1968; 1971) ; 
Mahgoub et al. (1977) who concluded that mycetoma infection causes 
deficiency in cell mediated  immune response. CD4/CD8 ratio is a 
reflection of health of immune system (Mary et al., 2005). The normal 
ratio is 1:4. However, in immunosuppressed and  HIV infection, the CD4 
is often decreased and CD8 increased so the ratio becomes less than 1. In 
this study, CD4/CD8 ratio in mycetoma treated patients (1.2:1), 
mycetoma untreated patients (1.2:1) and non-infected control (1.6:1).   
Thus, it seems that mycetoma infection has no effect on immune system. 
The total white blood cells (TWBC) count is used to investigate 
infections and unexplainable fever and monitor treatment which can 
cause leucopenia (Cheesburgh, 2004). In this study, the WBC count was 
not significantly different when treated and untreated mycetoma infected 
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patients were compared with non – infected control. This means TWBC 
count can not be used as diagnostic parameters. 
The deferential count of WBC provides information on different 
type of WBC present in the circulating blood (Cheesbourgh, 2005). The  
result of this investigation revealed that mycetoma infection has no effect 
on the percentage of neutrophils, basiophiles, eosinophils and 
lymphocytes in blood samples examined as these percentage are similar 
to those of non- infected control and the percentages remained within the 
normal range (Table,31)(Fig. 9).This   confirms the previous reports by 
Mahgoub (1967, 1971) and Mahgoub et al. (1977) which showed 
mycetoma infection has no effect on cell – mediated immune response. 
Finally it can be concluded that mycetoma infection has no effect 
on cell-mediated immune response as TWBC count and WBC differential 
count indicated. Also, it can be concluded that treatment may revert the 
effect of mycetoma infection on lymphocyte counts. Also, it can be 
concluded that neither TWBC count nor WBC deferential count could be 
used as means to diagnose mycetoma or monitoring treatment. 
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Chapter Five 
Conclusions   
From the results and findings of this study it can be concluded that: 
Males were more affected than females and the ratio was 4:1. Most 
of mycetoma patients were in the age group 15 – 25 years old. Students 
(20.4%), jobless (18.4%) and farmers (14.3%) were more affected than 
other occupations. Algazera State had the highest prevalence (34.7%)  of 
mycetoma and followed by Khartoum State (16.3%). 
The duration of the disease varied from 7 month to 30 years and 
the onsets of the disease in most of patients (73.5%) had no known 
history of trauma. Few patients (6.1%) had more than one lesion in their 
bodies, and the left foot was the major site of infection (34.7%). Most of 
the patients (83.7%) had no family history of mycetoma infection.  
Eumycetoma infection had higher prevalence (59.2%) than 
actinomycetoma infection (38.8%). The drug of choice used for treatment 
in eumycetoma infection was ketoconazole, and in actinomycetoma was a 
combination of Streptomycin, septrin and folic acid. 
Total white blood cells counts and differential counts in most of 
patients were normal count between 4050 - 6000cell⁄µl. and the mean 
value in untreated patients was 6081.5cell⁄µl, while in treated patients it 
was 6178.3cell⁄µl.    CD4 counts in untreated patients was significantly 
lower than in non- infected control and numerically lower than in treated 
patients it was 606.8cell⁄µl. CD8 counts in untreated patients were 
numerically higher than in treated patients and  non- infected controls. 
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CD4⁄CD8 ratio in all patients was 1.1:1. in new and treated patients 
the ratio was 1.2:1, and non infected control was (1.6:1).   
The drugs or mycetoma infection might have effect on CD4 and 
CD8 counts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
Recommendations 
Mycetoma is still one of the major health problem in Sudan, in this 
respect the Mycetoma Research Center is the most important centre in 
Sudan and it needs more support from government and society. 
Educations program and corporation between specialists and the 
media is needed to raise awareness levels using all communication 
channels to provide appropriate information on mode of infection, 
prevention and control of the disease. 
 Counting CD4 and CD8, to be used to study the immune status in 
mycetoma infection, need more research. 
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